Clinic News

Latest in Cardiology

• Identification of Frailty in Chronic Heart Failure
  What is the prevalence of frailty, classification performance, and agreement among three frailty assessment tools and three screening tools in patients with chronic heart failure (CHF)?
• Atrial Fibrillation and Biomarkers of Myocardial Fibrosis
  Are biomarkers of myocardial interstitial fibrosis (collagen type-I crosslinking [CCL+] and deposition [CD+]) associated with prevalent, incident, and recurrent atrial fibrillation (AF)?
• Cardiac Rehabilitation, Exercise Capacity, and Quality of Life in Heart Failure
  What is the impact of exercise cardiac rehabilitation (ExCR) on health-related quality of life (HRQoL) and exercise capacity in patients with heart failure (HF)?  
• Anatomic and Functional Assessment With CTA: Are Diagnostic Catheterizations a Way of the Past?
  In recent years, the evolution of coronary computed tomography angiography (CTA) has heralded its transition from a limited role in the exclusion of obstructive disease in selected low-risk patients to the forefront of cardiovascular imaging with diverse applications.
• Medscape and ACC Centers of Excellence
  A 79-Year-Old Woman With a Pacemaker and High Atrial RatesJeff S. Healey, MD, MSc, FRCPC; Jonathan P. Piccini, MD, MHS, FACC; Christian T. Ruff, MD, MPH
• Preventing Hypoxemia With Manual Ventilation During Endotrachial Intubation
  The goal of the PreVent trial was to evaluate bag-mask ventilation compared with no ventilation among critically ill patients undergoing endotracheal intubation.
• AHA Scientific Statement on Cardiorenal Syndrome
  The following are key points to remember from this American Heart Association (AHA) Scientific Statement about cardiorenal syndrome (CRS).
• FDA Allows Losartan With NMBA Level Below 9.82 ppm to Remain on Market
  In an effort to ensure patient access to losartan, the U.S. Food and Drug Administration (FDA) announced it will not object to certain manufacturers temporarily distributing losartan containing N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) above the interim acceptable intake limit of 0.96 parts per million (ppm) and below 9.82 ppm until the impurity can be eliminated. The agency […]
• Duration of Anticoagulation Post-PE: Things to Consider
  Pulmonary embolism (PE) is a common medical condition affecting over 250,000 patients in the United States each year.
• About 1 in 6 HFrEF Patients Develop Worsening HF Within 18 Months, NCDR Study Shows
  About one in six patients with heart failure with reduced ejection fraction (HFrEF) develop worsening HF within 18 months of initial HF diagnosis, according to a study published Feb. 25 in the Journal of the American College of Cardiology.